This is a PDF file of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting. Nature is providing this early version of the typeset paper as a service to our authors and readers. The text and figures will undergo copyediting and a proof review before the paper is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

In a preliminary experiment, 74 faba bean genotypes including winter genotypes (autumn-sown) and spring genotypes (spring-sown) and isogenic population pairs (tannin-containing v. tannin-free and vicine/convicine-high v. vicine/convicine-low), were analysed for the chemical composition of their seeds. A large variability was found for the main constituents (starch, protein and fibre). Autumn-sown genotypes contained 2·3% less proteins but 2·5% more starch in the seed dry matter (DM) than spring-sown genotypes. The vc− gene, which lowers the vicine and convicine contents, did not significantly modify the main seed components in the isogenic comparisons. The zt1 and zt2 genes, which eliminate condensed tannins in the seed coats, lowered by 2·1% the proportion of the seed coat in the DM. In the isogenic comparisons, the zt2 gene had a stronger effect than zt1 in reducing the total seed fibre and increasing the protein content.In a second experiment, from the original 74 genotypes, 12 contrasted genotypes were selected and multiplied for animal nutrition trials. Their chemical analysis confirmed the variability between the faba bean categories observed in Expt 1, but detailed chemical analyses illustrated the variability in amino acid, fatty acid, amylose and oligosaccharide composition, trypsin inhibitory activity, condensed tannins, lectins and phytic phosphorus contents.

Rituximab maintenance therapy was well tolerated but did not completely prevent relapses and persistent "grumbling" disease. These preliminary results remain to be confirmed by a randomized controlled trial currently in progress.

The SARS-CoV-2 B.1.617 lineage emerged in October 2020 in India. It has since then become dominant in some indian regions and further spread to many countries. The lineage includes three main subtypes (B1.617.1, B.1617.2 and B.1.617.3), which harbour diverse Spike mutations in the N-terminal domain (NTD) and the receptor binding domain (RBD) which may increase their immune evasion potential. B.1.617.2 is believed to spread faster than the other versions. Here, we isolated infectious B.1.617.2 from a traveller returning from India. We examined its sensitivity to monoclonal antibodies (mAbs) and to antibodies present in sera from COVID-19 convalescent individuals or vaccine recipients, in comparison to other viral lineages. B.1.617.2 was resistant to neutralization by some anti-NTD and anti-RBD mAbs, including Bamlanivimab, which were impaired in binding to the B.1.617.2 Spike. Sera from convalescent patients collected up to 12 months post symptoms and from Pfizer Comirnaty vaccine recipients were 3 to 6 fold less potent against B.1.617.2, relative to B.1.1.7. Sera from individuals having received one dose of AstraZeneca Vaxzevria barely inhibited B.1.617.2. Thus, B.1.617.2 spread is associated with an escape to antibodies targeting non-RBD and RBD Spike epitopes.